MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Ondine says UCL study shows Steriwave effective against Mucor fungus

ALN

Ondine Biomedical Inc on Monday said researchers from University College London found its Steriwave photodisinfection technology to be effective in killing the Mucor fungus, which can cause fatal infections in vulnerable hospital patients.

The data was presented at the 19th World Congress of the International Photodynamic Association in Shanghai.

Mucor, which causes mucormycosis, poses a serious risk to immunocompromised patients such as those undergoing bone marrow transplants. Mortality rates for mucormycosis often exceed 50%, and existing treatments are limited, often involving toxic antifungals and aggressive surgery.

According to UCL’s Colin Hopper and Aashvi Joshi, Steriwave ‘rapidly and safely’ decolonised the nose of fungal pathogens in vitro. The researchers said this represents a ‘major advance’ in infection prevention and could be deployed affordably in hospitals.

The study also showed that Steriwave enhanced the activity of existing antifungals like azoles, suggesting potential for combined topical and systemic treatment strategies.

Steriwave is already in use in hospitals in the UK and Canada to prevent surgical site and healthcare-associated infections. Ondine said the findings strengthen the case for broader adoption of the technology amid rising concerns over drug-resistant infections.

Ondine shares were 4.6% higher at 9.41 pence in London on Monday afternoon.

Copyright 2025 Alliance News Ltd. All Rights Reserved.